Clinical Trial
Tafenoquine for Chronic Babesia Featuring Severe Fatigue
This is an open-label trial investigating the effects of an off-label drug called tafenoquine (arakoda) on chronic Babesia in patients who experience severe fatigue.
Is this a virtual opportunity?
No, this trial requires in-person participation.
What are the location requirements?
You must be located in the USA. You must be located in or near New York City, or be able to travel there, for in-person study visits at the clinic.
Will there be in-person visits? If so, how many?
Yes, there will be at least 7 in-person visits.
What is the length of participation?
The length of participation is 6 months.
What health qualifications are required to participate?
Proof of babesia infection (we recommend iGeneX FISH testing) AND severe fatigue (patient-reported)
Will compensation be available?
Participants may be compensated up to $525, and limited travel reimbursement will be made available for those living outside NYC.